Home › Burkitt Lymphoma
Burkitt Lymphoma clinical trials recruiting in the U.S.
63 studies for Burkitt Lymphoma are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX21 studies
- Milwaukee, WI16 studies
- Philadelphia, PA16 studies
- New York City, NY14 studies
- Chicago, IL13 studies
- Cincinnati, OH12 studies
- Seattle, WA12 studies
- Atlanta, GA11 studies
- Aurora, CO10 studies
- Durham, NC10 studies
- Boston, MA10 studies
- Kansas City, MO10 studies
- Los Angeles, CA10 studies
- Washington, DC9 studies
- Orange, CA9 studies
- Minneapolis, MN9 studies
- Baldwin Park, CA9 studies
- Baltimore, MD8 studies
- Buffalo, NY8 studies
- Nashville, TN8 studies
- San Francisco, CA8 studies
- Ann Arbor, MI8 studies
- Columbus, OH8 studies
- Portland, OR8 studies
- Jacksonville, FL7 studies
- Greenburgh, NY7 studies
- Grand Rapids, MI7 studies
- Cleveland, OH7 studies
- Clifton, NJ7 studies
- San Antonio, TX7 studies
- Dallas, TX7 studies
- Oklahoma City, OK7 studies
- Richmond, VA7 studies
- Tampa, FL7 studies
- Birmingham, AL7 studies
- Providence, RI7 studies
- Salt Lake City, UT7 studies
- Pittsburgh, PA6 studies
- St. Petersburg, FL6 studies
- Queens, NY6 studies
By state
- Alabama7 studies
- Arizona7 studies
- Arkansas5 studies
- California20 studies
- Colorado13 studies
- Connecticut7 studies
- Delaware7 studies
- District of Columbia5 studies
- Florida15 studies
- Georgia11 studies
- Hawaii5 studies
- Idaho6 studies
- Illinois13 studies
- Indiana6 studies
- Iowa7 studies
- Kansas6 studies
- Kentucky5 studies
- Louisiana4 studies
- Maine4 studies
- Maryland11 studies
- Massachusetts10 studies
- Michigan10 studies
- Minnesota10 studies
- Mississippi4 studies
- Missouri8 studies
- Nebraska5 studies
- Nevada6 studies
- New Hampshire4 studies
- New Jersey8 studies
- New Mexico3 studies
- New York20 studies
- North Carolina13 studies
- North Dakota5 studies
- Ohio17 studies
- Oklahoma7 studies
- Oregon8 studies
- Pennsylvania18 studies
- Rhode Island7 studies
- South Carolina5 studies
- South Dakota5 studies
- Tennessee10 studies
- Texas24 studies
- Utah7 studies
- Vermont3 studies
- Virginia7 studies
- Washington12 studies
- West Virginia3 studies
- Wisconsin17 studies
Recently updated studies
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT03739814Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Sep 28, 2026 · NCT03223610A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
366 Days – 46 Years · All sexes · Updated Sep 28, 2026 · NCT06124157Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RecruitingPhase 2
365 Days · All sexes · Updated Sep 25, 2026 · NCT06317662Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06144606Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07648264Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Sep 17, 2026 · NCT06395103A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
RecruitingPhase 3
Ages 1 and older · All sexes · Updated Sep 17, 2026 · NCT07223021A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
RecruitingPhase 1
Ages 0 to 18 · All sexes · Updated Sep 16, 2026 · NCT06173518UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
RecruitingPhase 1/2
31 Days – 30 Years · All sexes · Updated Sep 14, 2026 · NCT04544592Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT03666000Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
RecruitingPhase 3
Ages 18 to 39 · All sexes · Updated Sep 2, 2026 · NCT03150693A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
Ages 1 to 30 · All sexes · Updated Sep 1, 2026 · NCT04546399Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Aug 25, 2026 · NCT05389423Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
Recruiting
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT06710418AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Aug 19, 2026 · NCT06137118Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
RecruitingPhase 2
Ages 7 to 25 · All sexes · Updated Aug 19, 2026 · NCT05082519AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06340737Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06287229Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
RecruitingPhase 2
Ages 15 and older · All sexes · Updated Aug 10, 2026 · NCT03136146LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RecruitingPhase 1
Ages 18 to 81 · All sexes · Updated Aug 6, 2026 · NCT05990465Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579Blinatumomab Consolidation in Real World
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT07117136Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT07069699From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.